Related Experiment Video
Updated: Jul 15, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
Design and Optimization of Benzoic Acid Inhibitors Targeting the EBNA1 DNA-Binding Interface
Garry R Smith1, Mark E McDonnell1, Yan Zhang1
1Fox Chase Therapeutics Discovery, Inc., 3805 Old Easton Road, Doylestown, Pennsylvania 18902, United States.
Abstract:
Epstein-Barr nuclear antigen 1 (EBNA1) is an essential viral DNA-binding protein required for maintenance of Epstein-Barr virus (EBV) episomes and is expressed in all EBV-associated malignancies, making it an attractive therapeutic target. Using fragment-based screening and X-ray crystallography, we identified a 2,3-disubstituted benzoic acid scaffold that binds at the EBNA1 DNA-binding interface. Structure-guided optimization revealed that the carboxylic acid pharmacophore engages Asn519 and Thr590, while electron-rich heterocycles are positioned between Lys477 and Lys586, forming a cation-π-cation "lysine sandwich" that drives potency. Iterative medicinal chemistry improved binding affinity and physicochemical stability, leading to compound 35 (VK-2019), a submicromolar EBNA1 to DNA binding inhibitor. Compound 35 demonstrated favorable drug-like properties and robust antitumor efficacy in EBV-positive xenograft models and has advanced to clinical evaluation. These studies define the structural determinants of EBNA1 inhibition and establish a framework for targeting viral genome-maintenance proteins with small molecules.
More Related Videos
10:01Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
09:33Phthalic Acid Ester-Binding DNA Aptamer Selection, Characterization, and Application to an Electrochemical Aptasensor
Published on: March 21, 2018
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Enzyme Inhibition
Inhibitors of Bacterial Protein Synthesis